Is Rifampicin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 4 valid registrations of Rifampicin, including RIFACIN 150MG CAP. (150 mg, Capsule, SAR 35.65); RIFACIN 300 MG CAPS (300 mg, Capsule, SAR 64.45); RIFADIN CAP 150 MG (150 mg, Capsule, hard, SAR 35.65); RIFADIN CAP 300 MG (300 mg, Capsule, hard, SAR 64.45).

Is Rifampicin approved by the US FDA?

Drugs@FDA lists 15 application product lines for Rifampicin, including RIMACTANE (Prescription); RIFADIN (Prescription); RIFAMPIN (Prescription); RIFAMPIN (Prescription); RIFAMPIN (Prescription).

Is Rifampicin on the WHO Model List of Essential Medicines?

Yes — 6.2.4. Antileprosy medicines (core list): Leprosy.

Are there safety signals or safety updates for Rifampicin?

EMA PRAC: 1 entry; US FDA: 4 entries (latest 2026-08-12).

Active substance

Rifampicin

SFDA 9
US FDA 15
Health Canada 2
US price lines 2
NHS prices 2
WHO EML 2
Safety 5

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
RIFACIN 150MG CAP.	150 mg	Capsule · Oral use	8 Blister	SAR 35.65	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
RIFACIN 300 MG CAPS	300 mg	Capsule · Oral use	8 Blister	SAR 64.45	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
RIFADIN CAP 150 MG	150 mg	Capsule, hard · Oral use	8 Blister	SAR 35.65	NCE · Prescription	sanofi-aventis	Valid
RIFADIN CAP 300 MG	300 mg	Capsule, hard · Oral use	8 Blister	SAR 64.45	NCE · Prescription	sanofi-aventis	Valid
RIAFAMPICIN	300 mg	Tablet · Oral use	10 Blister	SAR 26.95	Generic · Prescription	RIYADH PHARMA	Withdrawn by MAH · Not Marketed
RIAFAMPICIN	150 mg	Tablet · Oral use	10 Blister	SAR 15.90	Generic · Prescription	RIYADH PHARMA	Withdrawn by MAH · Not Marketed
RIMACTANE 150 MG CAP	150 mg	Capsule · Oral use	8 Blister	SAR 25.40	Generic · Prescription	SANDOZ	Invalid · Not Marketed
RIMACTANE 300 MG CAP	300 mg	Capsule · Oral use	8 Blister	SAR 48.35	Generic · Prescription	SANDOZ	Invalid · Not Marketed
RIMACTAZID 300MG TAB.	300 mg	Tablet · Oral use	20 Blister	SAR 121.00	Generic · Prescription	SANDOZ	Withdrawn by MAH · Not Marketed

Indications — CHI Daman Drug Formulary

BACTERIAL MENINGITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; BRUCELLOSIS; ENDOCARDITIS; OSTEOMYELITIS; PERITONITIS, PERITONEAL DIALYSIS-RELATED PERITONITIS; PHARYNGITIS; PREVENTION AND CHEMOPROPHYLAXIS OF BACTERIAL MENINGITIS- MENINGOCOCCAL INFECTIONS PREVENTION (CHEMOPROPHYLAXIS); PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS; TRAVEL RELATED INFECTIONS-TREATMENT; TUBERCULOSIS

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
RIMACTANE	300MG	capsule · oral	OXFORD PHARMS	Prescription	21 May 1971
RIFADIN	600MG/VIAL	injectable · injection	SANOFI AVENTIS US	Prescription	25 May 1989
RIFAMPIN	300MG; 150MG	capsule · oral	EPIC PHARMA LLC	Prescription	28 May 1997
RIFAMPIN	600MG/VIAL	injectable · injection	HIKMA PHARMS	Prescription	29 Oct 1999
RIFAMPIN	150MG; 300MG	capsule · oral	CHARTWELL MOLECULAR	Prescription	28 Mar 2008
RIFAMPIN	600MG/VIAL	injectable · injection	MYLAN LABS LTD	Prescription	22 May 2008
RIFAMPIN	600MG/VIAL	injectable · injection	EPIC PHARMA LLC	Prescription	21 Sep 2010
RIFAMPIN	150MG; 300MG	capsule · oral	LUPIN PHARMS	Prescription	21 Aug 2013
RIFAMPIN	600MG/VIAL	injectable · injection	FRESENIUS KABI USA	Prescription	21 Aug 2014
RIFAMPIN	600MG/VIAL	injectable · injection	HIKMA PHARMS	Prescription	3 Mar 2016
RIFAMPIN	150MG; 300MG	capsule · oral	NOVITIUM PHARMA	Prescription	29 Jun 2026
RIFADIN	300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons; 150MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	capsule · oral	SANOFI AVENTIS US	Discontinued	21 May 1971
RIFAMPIN	150MG; 300MG	capsule · oral	HIKMA PHARMS	Discontinued	14 Mar 2001
RIFAMPIN	600MG/VIAL	injectable · injection	AVET LIFESCIENCES	Discontinued	18 Aug 2014
RIFAMPIN	600MG/VIAL	injectable · injection	WATSON PHARMS TEVA	Discontinued	19 Jan 2016

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
ROFACT	00343617	300 MG	CAPSULE · ORAL	BAUSCH HEALTH, CANADA INC.
ROFACT	00393444	150 MG	CAPSULE · ORAL	BAUSCH HEALTH, CANADA INC.

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	RIFAMPIN 150 MG CAPSULE	$0.89776	per EA	30 Sep 2026
US NADAC	RIFAMPIN 300 MG CAPSULE	$0.67892	per EA	30 Sep 2026
NHS Drug Tariff	Rifampicin 100mg/5ml oral suspension	£4.82	120 ml	1 Oct 2026
NHS Drug Tariff	Rifampicin 300mg capsules	£140.14	100 capsule	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

WHO WHO Model List of Essential Medicines (2025)

6.2.4. Antileprosy medicines · core
Leprosy
Oral > Liquid: 20 mg per mL (EMLc) | Oral > Solid: 150 mg; 300 mg
6.2.5. Antituberculosis medicines · core
Tuberculosis
Oral > Liquid: 20 mg per mL (EMLc) | Oral > Solid: 150 mg; 300 mg

Safety signals and safety-related labeling changes

US FDA 12 Aug 2026 RIMACTANE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions
US FDA 5 Dec 2025 RIFADIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
US FDA 5 Dec 2025 RIFADIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
US FDA 5 Dec 2025 RIFATER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
EMA PRAC 1 Sep 2017 PRAC signal: Drug interaction between amlopdine and rifamipicin leading to reduced antihypertensive effect of amlodipine
Action for MAH: update of the product information: No

All safety entries for rifampicin →

Combinations containing Rifampicin

Isoniazid + rifampicin

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.